Travere wins full FDA approval for FILSPARI in FSGS; Q1 sales jump 88% to $105M

Filed May 4, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~1 min read

Key Changes

• high

  FILSPARI received full FDA approval for FSGS in April 2026, becoming the first and only approved medicine for this rare kidney disease affecting over 30,000 U.S. patients without nephrotic syndrome.

  MD&A: FILSPARI FSGS approval verify on EDGAR →
• high

  FILSPARI net sales surged 88% year-over-year to $105.2 million in Q1 2026, driven by continued IgAN launch momentum and the new FSGS approval.

  MD&A: Product revenue verify on EDGAR →
• high

  Travere received $40 million from CSL Vifor (Q4 2025) and $25 million from Mirum (April 2026) in milestone payments, strengthening cash position despite operating burn.

  MD&A: Milestone payments verify on EDGAR →